| Literature DB >> 25529801 |
Tomasz Wojcik1, Elzbieta Buczek1, Katarzyna Majzner2, Agnieszka Kolodziejczyk3, Justyna Miszczyk4, Patrycja Kaczara1, Wojciech Kwiatek4, Malgorzata Baranska2, Marek Szymonski3, Stefan Chlopicki5.
Abstract
Although anthracycline antibiotics have been successfully used for nearly half a century in the treatment of various malignancies, their use is limited by their cardiac and vascular toxicities, and the mechanisms of these toxicities are still not entirely clear. Herein, we comprehensively characterized cytotoxic effects of two structurally related anthracyclines, doxorubicin and daunorubicin. In nanomolar concentrations, both drugs induced DNA damage and increased nuclear area that were associated with their accumulation in the nucleus (doxorubicin ⩾50 nM and daunorubicin ⩾25 nM) as evidence by Raman microspectroscopy at 3820-4245 cm(-1). At low micromolar concentrations, doxorubicin (⩾5 μM) and daunorubicin (⩾1 μM) increased the generation of reactive oxygen species, decreased intracellular reduced glutathione, induced an alteration in endothelial elasticity and caused a reorganization of the F-actin cytoskeleton. In isolated mouse aortic rings, doxorubicin (⩾50 μM) was less potent than daunorubicin (⩾5 μM) in impairing the endothelium-dependent response. In summary, using a comprehensive endothelial profiling approach, we demonstrated clear-cut differences in the potencies to induce endotheliotoxic responses for two structurally similar chemotherapeutics, at a nuclear, cytosolic and membrane levels. Furthermore, our results suggest that the differences in the endothelial toxicities of doxorubicin and daunorubicin are linked to differences in their nuclear accumulation and the DNA damage-triggered response of the endothelium.Entities:
Keywords: Cytotoxicity; Daunorubicin; Doxorubicin; Endothelium; High-content screening
Mesh:
Substances:
Year: 2014 PMID: 25529801 DOI: 10.1016/j.tiv.2014.12.009
Source DB: PubMed Journal: Toxicol In Vitro ISSN: 0887-2333 Impact factor: 3.500